Search Results - "Fife, K."

Hedgehog pathway inhibitors come of age by Fife, K.

“…Linked Article: Dummer et al. Br J Dermatol 2020; 182:1369–1378…”
Get full text

Combined Radiotherapy and New Systemic Therapies – Have We Moved Beyond Palliation? by Fife, K., Bang, A.

“…The new systemic therapies for cancer are having major impacts on the prognosis of patients with advanced cancers, some achieving long-term survival with…”
Get full text

Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial by Basset-Séguin, N., Hauschild, A., Kunstfeld, R., Grob, J., Dréno, B., Mortier, L., Ascierto, P.A., Licitra, L., Dutriaux, C., Thomas, L., Meyer, N., Guillot, B., Dummer, R., Arenberger, P., Fife, K., Raimundo, A., Dika, E., Dimier, N., Fittipaldo, A., Xynos, I., Hansson, J.

“…The SafeTy Events in VIsmodEgib study (STEVIE, ClinicalTrials.gov, NCT01367665), assessed safety and efficacy of vismodegib—a first-in-class Hedgehog pathway…”
Get full text

Challenges and new horizons in the management of advanced basal cell carcinoma: a UK perspective by Lear, J T, Corner, C, Dziewulski, P, Fife, K, Ross, G L, Varma, S, Harwood, C A

“…Basal cell carcinoma (BCC) is a common malignancy with a good prognosis in the majority of cases. However, some BCC patients develop a more advanced disease…”
Get full text

British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma 2020 by Keohane, S.G., Botting, J., Budny, P.G., Dolan, O.M., Fife, K., Harwood, C.A., Mallipeddi, R., Marsden, J.R., Motley, R.J., Newlands, C., Proby, C., Rembielak, A., Slater, D.N., Smithson, J.A., Buckley, P., Fairbrother, P., Hashme, M., Mohd Mustapa, M.F., Exton, L.S.

“…Plain language summary available online…”
Get full text

British Association of Dermatologists guidelines for the management of adults with basal cell carcinoma 2021 by Nasr, I., McGrath, E.J., Harwood, C.A., Botting, J., Buckley, P., Budny, P.G., Fairbrother, P., Fife, K., Gupta, G., Hashme, M., Hoey, S., Lear, J.T., Mallipeddi, R., Mallon, E., Motley, R.J., Newlands, C., Newman, J., Pynn, E.V., Shroff, N., Slater, D.N., Exton, L.S., Mohd Mustapa, M.F., Ezejimofor, M.C.

“…Linked Comment: M.D. Moncrieff and J.P. Nobes. Br J Dermatol 2021; 185:877. Plain language summary available online…”
Get full text

Variability in Kidney Cancer Treatment and Survival in England: Results of a National Cohort Study by Fife, K., Pearson, C., Knott, C.S., Greaves, A., Stewart, G.D.

“…To establish whether there are geographic differences in treatments and outcomes for patients with kidney cancer (KC) in England which could potentially be…”
Get full text

Real-world treatment sequencing and survival in previously treated advanced renal cell carcinoma patients receiving nivolumab monotherapy: a UK retrospective cohort study by Waddell, T, Fife, K, Griffiths, R, Sharma, A, Dhokia, P, Groves, L, Hurst, M, Tsang, C, Sugrue, D, McKenna, S, Houghton, J, Carroll, R

“…The CheckMate 025 trial established nivolumab monotherapy as one of the standards of care in previously treated advanced or metastatic renal cell carcinoma…”
Get full text

Single-Fraction Stereotactic Ablative Body Radiotherapy for Primary and Extracranial Oligometastatic Cancers by Greenwood, H, Hassan, J, Fife, K, Ajithkumar, T V, Thippu Jayaprakash, K

“…Stereotactic ablative body radiotherapy (SABR) consists of delivering high doses of ionising radiation, typically across three to eight fractions with high…”
Get full text

Determinants of Outcome in Melanoma Patients With Cerebral Metastases by FIFE, K. M, COLMAN, M. H, MILTON, G. W, MCCARTHY, W. H, THOMPSON, J. F, STEVENS, G. N, FIRTH, I. C, MOON, D, SHANNON, K. F, HARMAN, R, PETERSEN-SCHAEFER, K, ZACEST, A. C, BESSER, M

“…To analyze prognostic factors, effects of treatment, and survival for patients with cerebral metastases from melanoma. All melanoma patients with cerebral…”
Get full text

Radiation-Induced Lymphopenia and Virologic Outcomes in HIV-Positive Patients Undergoing Radiation for Cancer by Ellsworth, S, Rebesco, G, Fife, K, Grossman, S

Get full text

Radiotherapy and Systemic Treatment for Non-melanoma Skin Cancer in the COVID-19 Pandemic by Rembielak, A., Sykes, A.J., Fife, K., Challapalli, A., Nobes, J.P.

Get full text

Cemiplimab in advanced cutaneous squamous cell carcinoma: the UK experience from the Named Patient Scheme by Challapalli, A., Watkins, S., Cogill, G., Stewart, G., Ellis, S., Sykes, A., Nobes, J., Yip, K., Barthakur, U., Board, R., Gadve, A., O’Toole, L., Kent, C., Mackenzie, J., Papa, S., Fusi, A., Fife, K.

Get full text

Treatable causes of diarrhoea in patients on tyrosine kinase inhibitors for metastatic renal cell carcinoma by Lightowlers, S.V., Greef, B., Eisen, T., Matakidou, A., Fife, K., Cameron, E.A.

Get full text

Signaling to the Nucleus by an L-Type Calcium Channel-Calmodulin Complex through the MAP Kinase Pathway by Dolmetsch, Ricardo E., Pajvani, Urvi, Fife, Katherine, Spotts, James M., Greenberg, Michael E.

“…Increases in the intracellular concentration of calcium ([ Ca2+]i) activate various signaling pathways that lead to the expression of genes that are essential…”
Get full text

Cabozantinib in metastatic renal cell carcinoma (mRCC): Data from UK expanded access program (EAP) by Gomez de Liano Lista, A., Venugopal, B., Fife, K., Symeonides, S., Vasudev, N.S., Rudman, S.M., Vohra, S., Khasati, L., Pettinger, C., Szabados, B., Morrison, L., Powles, T., Boleti, E.

Get full text

Metastatic clear cell renal cell carcinoma patients with ECOG performance status 2 treated with pazopanib: The Pazo2 trial of efficacy and safety by Porfiri, E., Pirrie, S., Hodgkins, A.-M., Farrugia, D., Fife, K., McDonald-Smith, C., Vasudev, N.S., Nixon, G., James, N.D., Stubbs, C.

Get full text

A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK) by Powles, T., Brown, J., Larkin, J., Jones, R., Ralph, C., Hawkins, R., Chowdhury, S., Boleti, E., Bhal, A., Fife, K., Webb, A., Crabb, S., Geldart, T., Hill, R., Dunlop, J., Hall, P.E., McLaren, D., Ackerman, C., Beltran, L., Nathan, P.

“…Preclinical work suggests SRC proteins have a role in the development of resistance to vascular endothelial growth factor (VEGF) targeted therapy in metastatic…”
Get full text

CERES, a retrospective study of patients with advanced renal cell carcinoma who received cabozantinib as part of the UK Managed Access Program: Baseline characteristics and clinical outcomes by Szabados, B., Michael, A., Powles, T., Fife, K., Klair, B., Perrot, V., Venugopal, B.

Get full text

17: Comparative analysis of ESwab™ and standard collection systems for nugent scoring in the diagnosis of bacterial vaginosis by Rivers, C.A, Beqaj, S.S, Schwebke, J.R, Lebed, J, Smith, B, Farrell, M, Nyirjesy, P, Davis, T, Fuller, D, Fife, K

Get full text